NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Eisai Co., Ltd. (OTCPK:ESALF) has reported annual figures. The forecasts are pretty good for Leqembi, absolutely in line with our expectations for considerable growth. We believe they far exceed ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

And more pharma news updates from Pharmalittle.